logo
Fed paper says risk of falling back to near zero rates still in play

Fed paper says risk of falling back to near zero rates still in play

Reuters07-07-2025
July 7 (Reuters) - The prospect of the Federal Reserve once again setting its short-term interest rate target at near zero levels at some point in coming years remains real despite current relatively high levels of short-term borrowing costs, a new paper, opens new tab published jointly between the New York and San Francisco Federal Reserve banks said.
The medium- to long-term risk that the central bank's interest rate target will return to super low levels 'is currently at the lower end of the range observed over the past fifteen years,' said a paper that counted New York Fed President John Williams as a co-author. It was published on Monday. But the researchers added the chance of a return to near-zero rates 'remains significant over the medium to long term…due to recent elevated uncertainty.'
A near-zero federal funds rate target is associated with troubled economic times and their aftermaths. The Fed pegged its short-term interest rate target at such levels from 2008 and the onset of the financial crisis until late 2015, and found itself again at such levels in March 2020 due to the COVID-19 pandemic, before hiking interest rates aggressively starting into the spring of 2022 to combat the worst inflation readings seen in decades.
A near zero level for the interest rate target the Fed uses to achieve its job and employment mandates creates substantial challenges for central bankers. To provide stimulus beyond what a super low target can provide, officials have had to turn to controversial bond buying programs aimed at lowering long-term rates, which have in turn massively increased the size of the Fed's balance sheet. The Fed has also had to resort to communications strategies which officials also hoped would bolster the stimulative power of low rates.
The recent chapters of hitting near-zero rates came during what had been a multi-decade trend of declining rates amid a long-running trend of declining inflation pressures.
The experience of the last few years has ushered in a new landscape for the central bank. High levels of pandemic-driven inflation have cooled considerably. But the Fed, at a current target rate of between 4.25% and 4.5%, is still at a level that is relatively high relative to recent years' experience. It also faces considerable uncertainty over the outlook due to trade policy.
As of June, Fed officials expected to cut their target to 3.4% by 2027 and to start on that path this year. The central bank is also being pressured by President Donald Trump for aggressive easings.
Meanwhile, officials have also been revising up the forecast of the rate that's neutral relative to the economy's performance. Now at 3%, that projection as well as the June forecasts suggests the Fed may have more of a buffer to cut rates without hitting zero relative to recent years.
The paper, which based its analysis on interest rate derivatives, noted that even with the current buffer, the interest-rate outlook is complex. The risk of hitting near-zero rates 'tends to fall with higher expected levels of interest rates and tends to rise with interest rate uncertainty," the authors wrote.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial
Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial

Reuters

time12 minutes ago

  • Reuters

Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial

July 28 (Reuters) - Celcuity (CELC.O), opens new tab said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record high. The drug, gedatolisib, in combination with Pfizer's (PFE.N), opens new tab Ibrance and AstraZeneca's (AZN.L), opens new tab endocrine therapy Faslodex, reduced the risk of disease progression or death by 76%, compared to Faslodex alone in previously treated HR+/HER2- advanced breast cancer patients. HR+/HER2- breast cancer accounts for about 70% of all breast cancers. The study showed "unprecedented results", Leerink Partners analyst Andrew Berens said. Gedatolisib could become a new standard of care as a second-line treatment in breast cancer, especially in the community settings, Berens said. Celcuity's triple combination treatment helped patients live for an average of 9.3 months without progression of the disease, compared to about two months with Faslodex. Gedatolisib belongs to a class of drugs called PAM inhibitors, which include Novartis' (NOVN.S), opens new tab Afinitor and AstraZeneca's Truqap. Celcuity projects revenue potential of $5 billion for the treatment in the second-line treatment setting. The treatment was better tolerated in the late-stage trial than a previous early-stage study, with lower rates of high blood sugar and inflammation in the tissue lining the mouth, the company said, without offering further details. The study also showed that a double combination of gedatolisib and Ibrance increased survival without progression of the disease in patients by 7.4 months on average, compared to about two months with Faslodex. Celcuity plans to report full results from the late-stage study and data from a separate trial in patients whose tumors had alterations in some genes later this year. It expects to apply for U.S. marketing approval in the fourth quarter. Shares of the Minnesota-based firm more than doubled to $38.02 in early trading.

Megyn Kelly hires former MAGA megastar for plum role at her growing media empire
Megyn Kelly hires former MAGA megastar for plum role at her growing media empire

Daily Mail​

time15 minutes ago

  • Daily Mail​

Megyn Kelly hires former MAGA megastar for plum role at her growing media empire

Megyn Kelly has hired former top Trump aide Hope Hicks to be chief operating officer at her podcasting company Devil May Care Media. Kelly announced Hicks' hiring Monday morning in a statement, where she hailed Hicks as 'exactly the kind of woman I want running my company with me.' '[S]trong, smart, strategic and the embodiment of class and poise,' she said of the 36-year-old senior advisor to the first Trump administration, who will now help Kelly grow Devil May Care as it expands its slate of podcasts. The brand is also set to hire a new set of stars as well. Personalities under the Devil May Care Umbrella already include the likes of Mark Halperin, Link Lauren, Emily Jashinsky and Maureen Callahan. 'Megyn has used her talent, integrity, and unparalleled credibility to create content unlike anything else available today,' said Hicks of the venture. 'In the past several months, she has used her impeccable eye for talent and ever-growing platform to launch other worthy names under the MK Media umbrella with impressive results.' This is a developing story; please check back for updates...

UnitedHealth investors may seek roadmap on costs as Hemsley takes center stage
UnitedHealth investors may seek roadmap on costs as Hemsley takes center stage

Reuters

time42 minutes ago

  • Reuters

UnitedHealth investors may seek roadmap on costs as Hemsley takes center stage

July 28 (Reuters) - UnitedHealth's (UNH.N), opens new tab newly returned CEO, Stephen Hemsley, will likely face investor scrutiny over the largest U.S. health insurance and services company's efforts to rein in the elevated medical costs behind the withdrawal of its annual forecast. Hemsley returned to the role in May following the abrupt departure of then-CEO Andrew Witty, who stepped down amid rising operational and financial pressures. The company's decision in May to withdraw its 2025 earnings forecast due to soaring medical costs and Medicare-related challenges sent its shares tumbling. So far this year, UnitedHealth's stock has plunged more than 40%, dragging down the broader managed care sector with it. "Investors will be looking for confidence that he (Hemsley) has got a handle on things and that he understands where things may have gone wrong and how they are going to correct it," said James Harlow, senior vice president at Novare Capital Management, which owns 46,333 shares of the healthcare company. Hemsley, who ran the company from 2006 to 2017, has promised to rebuild trust, telling shareholders last month that regaining their confidence is a top priority. The pressure is compounded by a federal investigation into UnitedHealth's Medicare billing practices. The company recently confirmed it was cooperating with both criminal and civil inquiries from the U.S. Department of Justice. These regulatory woes have only added to the uncertainty facing the insurer. Wall Street analysts have lowered expectations throughout this month. Analysts expect a profit of $4.48 per share for the second quarter, according to data compiled by LSEG. That compares with expectations of $5.70 per share in May, when the company suspended its annual profit forecast. UnitedHealth plans to establish "a prudent 2025 earnings outlook and offer initial perspectives for 2026," the company had said in June. "Ultimately, on Tuesday, what we'd expect is more clarity on the way would expect a strategy, a roadmap laid out," said Sahil Bhatia, managing director of life sciences at Manning & Napier. "I think one of the big issues over the last few months has been just the we would expect more consistent execution going forward after laying out that roadmap," Bhatia said. At least two investors said they anticipate UnitedHealth will reset its 2025 profit forecast in the range of $18 to $20 per share, far below the company's previous outlook of $26 to $26.50. This might be conservative but is an appropriate start for Hemsley's first call, said Jeff Jonas, portfolio manager at Gabelli Funds. UnitedHealth has previously built a reputation to guide conservatively and raise its outlook as the year progresses. But this time, investors warn, withholding guidance altogether would be damaging. "If they continue to not give an EPS outlook for 2025, that will be damaging," Harlow added. Apart from financial turbulence, the company has also faced reputational challenges. It has moved to ease prior authorization requirements after a public outcry following the killing of a UnitedHealth executive last December. The Optum unit, once a growth driver for UnitedHealth, has also emerged as a key area of concern. Last quarter, the company flagged "unanticipated changes" in its Optum business that impacted planned 2025 reimbursements. "Among all the overhangs, Optum Health remains the biggest concern," said Deutsche Bank analyst George Hill. UnitedHealth has also grappled with the fallout from a major cyberattack last year that disrupted claims processing across its Change Healthcare unit.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store